AIMED, a resident of the Skolkovo Foundation's Biomedical Technologies Cluster, has signed a one-year contract with Novartis. A global pharmaceutical company will support the community-based Moles Solution, which allows for the detection of skin cancers such as melanoma using an ordinary smartphone and artificial intelligence technologies.
The use of innovative solutions based on multifactorial neural networks made it possible to achieve the accuracy of detecting malignant neoplasms at the level of leading oncodermatologists. The technology was developed and tested in cooperation with the Privolzhsky Research Medical University of the Ministry of Health of Russia, one of the leading centers for skin oncology in our country. The application for smartphones on Android and iOS platforms is free of charge.
Alexey Burdakov, co-founder and CTO of AIMED: “The simplicity and affordability of a self-examination solution for skin health makes it possible for the first time to carry out revolutionary mass screening of the population with the aim of early detection of malignant skin neoplasms. In 2021, with the support of the Novartis company and the Ministry of Health of the Nizhny Novgorod Region, within the framework of the Region without Melanoma program, we plan to conduct a mass screening of the population. Our solution allows to reduce the burden on oncodermatologists and make their work more efficient in the framework of face-to-face appointments or using telemedicine means.”
Ekaterina Ostrovskaya, Medical Director of Novartis Oncology: “At Novartis we are working hard to make the path to early and effective diagnosis of melanoma easier and more convenient, and we see great potential in partnership with platforms that allow us to achieve this goal. After all, if the doctor manages to identify a dangerous disease at the very beginning, this has a positive effect on the result of subsequent therapy. Now we spend most of our lives online, but this should not interfere with timely care for our health. The project on remote diagnostics About moles gives users the opportunity to take the first step towards a more responsible attitude towards themselves, simply by checking moles with a smartphone and, in case of suspicious signs, consult a doctor.”
Kamila Zarubina, Director of Acceleration, Skolkovo Foundation's Biomedical Technologies Cluster: “Timely diagnostics of skin cancer over the past 10 years has grown from 71% to 82%, which helps to achieve high efficiency in the treatment of patients with melanoma or basal cell skin cancer. Approximately 90% of patients who were promptly diagnosed and treated in the early stages (less than 2 cm, without invasion into the underlying tissues) live more than 5 years, which is equivalent to a cure in this nosology. The cooperation of the AIMED startup with the global pharmaceutical company Novartis and the Ministry of Health of the Nizhny Novgorod Region takes the project to a new level. The Skolkovo Foundation's biomedical technology cluster supports developments aimed at early detection of oncological diseases. In this regard, we are very pleased with the success of our member who has developed an application based on artificial intelligence technologies for the diagnosis of melanoma and basal cell skin cancer. We hope that the project will successfully and promptly go through all the stages necessary for the implementation of this development into real clinical practice. ”
The solution About moles is included in the case map of the international program “Global challenge - artificial intelligence for sustainable development” project Sk[ai]Hub.
AIMED is a Russian startup, a developer of innovative IT solutions for medical diagnostics of oncology using artificial intelligence technologies. Resident of the Skolkovo innovation center. The main project is the project About moles, aimed at detecting malignant neoplasms of the skin based on photographs using neural network technologies. Website: www.prorodinki.ru.
Novartis Corporation is a global pharmaceutical corporation, the world's second largest pharmaceutical company, and the second largest pharmaceutical manufacturer in Europe by market share. The company operates in 140 countries and is headquartered in Basel, Switzerland. Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and Pharmaceutical Research and Manufacturers of America (PhRMA). It takes 52nd place in the Forbes Global 2000 list. Website: www.novartis.ru.